DETAILS, FICTION AND CLINICAL EFFECTIVENESS OF ABBV-744 IN AML PATIENTS

In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Members will obtain treatment right up until disorder progression or perhaps the participants are not able to tolerate the study drugs.There may be better treatment load for participants Within this trial compared to the